...they like to scalp also! As the hype dies down they will liquidate for nice profit. IMHO...Be wise, not greedy. Fundamentals highly speculative and have not even receiving approval for trials from FDA.
As noted: "...investors shouldn't forget that dementia conditions are extraordinarily difficult to treat. Additionally, the new multigene therapy might be on the cutting edge, but it might also be pushing the boundaries of what's realistically possible with our current understanding of biology. So although Axovant Sciences has a new outlook, don't forget there's a long way to go before the company even has a shot at being a commercial success."
IMHO...it is a speculative trade... which has reached its zenith.
News 
Market Data 
Discover 
